What Is Stansberry’s Company To Dominate The Health Market With A Weight-Loss Treatment?

A big story in health care is set to play out in the coming years. Dr. David Eifrig and Thomas Carroll – editor and senior analyst, respectively, of Prosperity Investor – are joining forces today to explain why.

A recent Food and Drug Administration announcement could enable one company to dominate this health market with what might be a game-changing weight-loss treatment.

According to Stansberry’s experts, the drug this company has created is poised to not only disrupt the weight-loss and weight-management market… but also the sales of some of the biggest medical markets in the U.S. today.

Click here for all the details.

Stansberry Research’s Discovery of FDA Approval Stories

Stansberry Research has frequently identified revolutionary medical improvements even before they are approved by the FDA. They have advised their readers on how to generate double- and triple-digit gains within a few months of the publication of stories.

Tom Caroll, a Senior Analyst at Stansberry Research recently presented what the team has discovered recently in the medical field. Read further to learn the details.

According to Stansberry’s analysts, a small portion of the market is receiving an influx of capital and is expected to rise by as much as 842% during the following four years.

And they located ONE business in charge of everything. A business that is situated to benefit greatly from this phenomenal expansion. That’s because they have a ground-breaking medication that could cure an illness affecting 125 million Americans right now.

This medication could also help prevent 63 other diseases.

If you are wondering how Stansberry got access to this information, here are few words about the team.

Who Is Tom Caroll And The Team Behind Him?

As we mentioned above, Tom Caroll is a Senior Analyst at Stansberry Research. He’s been investing in the healthcare space for almost three decades. He has been working on Wall Street and meeting with CEOs of the biggest healthcare companies in the world.

His work has been recognized and he has been awarded multiple times.

In 2019, he joined Stansberry, where he teamed up with a group of editors who shared the same goal: to demonstrate to their readers how to benefit from the vast expansion of the healthcare system that has occurred since the Covid pandemic.

Tom Caroll works closely with Dr. David Eifrig and John Engel.

Doc is an M.D., MBA Wall Street veteran who served inside Goldman Sachs as well as Chase Manhattan. He has one of the best track records of any analyst at Stansberry Research. He was part of a team that helped start a small biomedical company that eventually sold gene therapy technology to Roche for $124 million a decade ago.

John Engel is a research scientist and world-class tech and biotech analyst. He obtained his Master of Science from Johns Hopkins University before working for prominent pharmaceutical firms and biotech start-ups. At Stansberry Research, he’s worked on our elite emerging technology letter Stansberry Venture Technology as well as Stansberry Innovations Report.

They track innovations… technologies… drug development… and healthcare infrastructure. They know what is going on and what to be expected in the close future.

The FDA Could Approve the Most Important Drug of Our Lifetimes on June 26

Tom and Stansberry’s team believe that this summer, as soon as June 26, we’ll see results from an FDA ruling that will potentially cause hundreds of billions of dollars to pour into one healthcare company.

Once the FDA approves this drug, people will learn that it’s THE most effective in the world at causing weight loss. There’s no other chemical compound that comes close.

A research study published by The New England Journal of Medicine (NEJM) shows this drug was TWICE as powerful. It beat the active ingredient in Ozempic (drug for diabetes) and Wegovy (weight loss drug the FDA approved last year) on nearly every single level.

While this chemical compound is still relatively unknown, there’s still time for anyone to get in early on the most effective weight loss treatment discovered so far.

As soon as June 26, an FDA announcement could enable this company to dominate an emerging health market set to grow 842% while treating more than 70 diseases. This is the kind of rare moneymaking situation we’ve seen turn a $10,000 stake into $75,800 in just four years.

How To Invest in this company?

Here are the steps that Tom Caroll is recommending you take now:

Step One: Buy “The Ultimate Weight Loss Drug”.

There is finally an answer to many people’s desires to achieve and maintain a healthy weight relatively easily.

The company behind this project most likely is going to make enough to supply the United States and beyond. To meet the anticipated demand, they already have TWO manufacturing plants under development on American land.

FDA approval is most likely just weeks or even days away.

Tom has spent the last few weeks working on a report called: “The Ultimate Weight Loss Drug”, that he recommends you read and take action on right away.

His expectation is you’ll be able to buy the stock, hold it and potentially collect the incredible gains for long time.

Step Two: Buy These “Forever Stocks”.

If you want to increase your wealth using the markets’ lowest-risk wealth compounders, you should pay attention to Tom’s selection of greatest stocks. He calls them “forever stocks.”

Forever stocks come from a market segment that is known for consistently outpacing inflation.

All necessary information is in a report called: 7 “Forever” Health Stocks to Potentially Double the Market, Every Year.

The stocks in this report are proven to be the best inflation hedge in the markets, twice as good as gold.

Tom’s expectations are these stocks to compound your wealth by at least 20% per year. They will carry less risk than almost any other investment in the world with likely DOUBLE the returns of the overall market in the coming years.

Tom’s recommendation is to buy them all and hold onto them forever. You can either give them to your children and grandkids or sell them when you need the money to support your retirement.

But even if you devote just 5% or 10% of your investment funds to this strategy, you’ll be much better off financially and worry-free than you are with any investment you probably currently own.

Step Three: Position Yourself for 3 Bonus Picks with 10x Potential in Health Care.

As you know, the biggest winners in healthcare will be the innovators. Tom has put the names he is recommending in a report entitled: 3 Chances at 1,000%-Plus Gains in Health Care.

Inside you will find:

• One of the companies he is naming in this report has 10x potential. The team created a simple, at-home test for an extremely dangerous and common type of cancer. It’s already approved by the FDA, it’s covered by Medicare, and it’s covered by some of the largest insurers in the largest states.

• The second business is utilizing the potential of medical AI and also has a 10x potential. Its portable device connects to any doctor’s smartphone and replaces machines that are 10 times more expensive. Additionally, it makes patient screening available at the point of care. Therefore, patients are no longer required to wait at the hospital for long periods of time for a specialist.

• The third company of the three Bonus Picks is a pure biotech play. It has a potential for astronomical gains when a groundbreaking drug wins approval.

There’s only one way to access the incredible work Tom and his team uncovered. Have you heard of Prosperity Investor? Here are few words about their service.

What Is Prosperity Investor?

The Property Investor team looks for investments that will not only provide the opportunity to create generational wealth but will improve the quality and length of our lives.

They believe the technology available today will be embraced and deployed across the spectrum of care. The time to invest is now.

The foundation of the investing approach in Prosperity Investor involves “Forever healthcare Stocks.” Recommendation is to hold those stocks for a decade or more if you can.

How Much Is Prosperity Investor?

You can buy TWO years of Prosperity Investor for a one-time payment of $2,500 HERE. This is an $11,000 value of research for over 77% off.

Your order will be covered by Stansberry Research’s 30-day 100% satisfaction guarantee. No cash refunds. They offer 100% Stansberry Credit.

What Is Included with Prosperity Investor offer?

Here is a list of benefits included in this offer:

• 77% OFF TWO YEARS of Prosperity Investor ($11,000 value).
• Instant access to the Prosperity Investor Model Portfolio.
• Special Updates & Alerts throughout the month.
• Health & Wealth Bulletin. This is a daily newsletter, full of topics and tips about health and retirement. It will be delivered to your inbox Monday through Friday at 3:30 p.m. ET.
• Special Report: The Ultimate Weight Loss Drug.
• Special Report: 7 “Forever” Health Stocks to Potentially Double the Market, Every Year.
• Special Report: 3 Chances at 1,000%-Plus Gains in Health Care.
• FREE BONUS: Manage Your No. 1 Asset! Four Things to Save Your Money and Life ($999 value). Everything you need to know about the Medicare program. How much you should budget for health care in retirement, and how you can make real money with HMOs. Tom even names some bonus health care stocks to keep on your radar.
• FREE BONUS: The Future of Health Care Panel ($999 value).
• And more!

Final Words

Over the past 18 months, volatility has affected some markets more severely than others. Health care can be super volatile, or it can be very defensive. If you only invest in biotech stocks that depend on the outcomes of clinical trials, your investments may be volatile. On the other side, you could also invest in managed care organization. Like a huge health insurer whose annual revenue increases year after year. Prosperity Investor does all kind of research in the health care space.

Ready To Try Prosperity Investor? Click Here For The Best Price + Bonuses